cisatracurium has been researched along with Breast Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ma, W; Yang, X | 1 |
| Farokhnia, F; Fazli, M; Khan, ZH; Maghsoudloo, M; Makarem, J; Zanjani, AP | 1 |
2 other study(ies) available for cisatracurium and Breast Neoplasms
| Article | Year |
|---|---|
Cisatracurium inhibits the proliferation, migration and invasion of breast cancer cells by regulating the expression of miR-3174.
Topics: Atracurium; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Female; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; MicroRNAs; Neoplasm Invasiveness; Up-Regulation | 2020 |
Chemotherapy alters cisatracurium induced neuromuscular blockade characteristics: A prospective cohort study.
Topics: Adult; Anesthesia, General; Antineoplastic Combined Chemotherapy Protocols; Atracurium; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Mastectomy; Middle Aged; Monitoring, Intraoperative; Neoadjuvant Therapy; Neuromuscular Blockade; Neuromuscular Junction; Neuromuscular Nondepolarizing Agents; Prospective Studies | 2017 |